Trial Profile

A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amisulpride (Primary)
Indications Schizophrenia
Focus Adverse reactions; Registrational
Acronyms NOVA3
Sponsors LB Pharmaceuticals

Most Recent Events

27 Jan 2026 Status changed from planning to not yet recruiting.
14 Oct 2025 According to LB Pharmaceuticals media release, the trial is expected to initiate in 2026
31 Mar 2025 According to LB Pharmaceuticals media release, the company plans to initiate this study in Q4 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com